RxDoctor Payments Data

Ijeoma Asota, MD

Cornea and External Diseases Specialist · Phoenix, AZNPI 1346405321

Payments from drug & device makers

$3,857in general payments, 2019–2025

Across 139 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$858
  • Biotissue Holdings Inc.$437
  • Novartis$378
  • Glaukos Corporation$343
  • Rxsight Inc$277
  • Sun Pharmaceutical Industries Inc.$275
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$391%
  • Food & beverage$3,81899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$417,905
Medicare patients
498
Services billed
2,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj20$672,398
RestasisCyclosporine41$46,783
Prednisolone Acetate1,266$41,746
ZirganGanciclovir31$18,314
ValacyclovirValacyclovir Hcl173$15,117
XiidraLifitegrast12$8,734
Cyclosporine14$6,707
Ketorolac Tromethamine159$6,262
Ofloxacin513$5,856
Difluprednate22$3,746
ErythromycinErythromycin Base172$2,084
Loteprednol Etabonate15$1,973
Fluorometholone14$1,311
Acyclovir70$1,244
MoxifloxacinMoxifloxacin Hcl24$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$858$672,39820 claims
AbbVieRestasis$67$46,78341 claims
Bausch & Lomb Americas Inc.Zirgan, Xiidra$240$27,04843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Phoenix

Where these figures come from

Is this you, or does something look wrong? →